Evaluation of P53 Level and It's Relation to Iron Status in Acute Myeloid Leukemia

Section: Research Paper
Issue
Vol. 48 No. 1 (2026): Volume 48 Issue 1
Pages
78-89

Keywords:

Leukemia, p53, Serum Iron, TIBC, transferrin saturation

Abstract

Background: Mutations in the Tumor suppressor protein53 gene are among the most common genetic alterations observed in human cancers. Iron metabolism may regulate protein53 activity, while protein53 can also influence iron homeostasis.


Aims: To evaluate the level of protein53 in acute myeloid leukemia patients and find the relation between protein53 level and iron status in controls and patients and its relation to disease outcome.


Methods: This case-control study was conducted in Nineveh governorate at Al-Hadbaa Specialized Hospital and Ibn-Sina Teaching Hospital from January to August 2025. It included 44 newly diagnosed acute myeloid leukemia patients and 44 healthy controls. Hematological and biochemical investigations included: complete blood picture, bone marrow aspirate and flowcytometry, serum protein53 and iron studies.


Results: The mean age was (32.95±23.966) years for patients and controls, with a male predominance. There was a statistically significant inverse correlation between protein53 levels and age. Protein 53 levels were higher in patients (141.65±109.546 ng/dl) than controls (95.69±66.428 ng/dl). Serum iron (23.45±11.42 µmol/L) and total iron binding capacity (108.32±47.02 µmol/L) were significantly high in patients. Lower protein53 levels were associated with incomplete remission. Significant correlations were observed between protein53 and serum iron in incomplete remission patients and with total iron-binding capacity in deceased patients.


Conclusion: Serum protein53 levels were increased in patients and associated with poor outcomes, suggesting a supportive diagnostic and prognostic role when combined with other markers.

References

  1. Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(3):502–526. Doi: https://doi.org/10.1002/ajh.26822
  2. Emadi A, Karp JE. Acute leukemia: an illustrated guide to diagnosis and treatment. New York: Springer Publishing Company; 2017.
  3. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70–87. Doi: https://doi.org/10.1016/j.blre.2019.04.005.
  4. Bain BJ, Béné MC. Morphological and immunophenotypic clues to the WHO categories of acute myeloid leukaemia. Acta Haematol. 2019;141(4):232–44. Doi: https://doi.org/10.1159/000496097.
  5. Zhou Y, Huang G, Cai X, Liu Y, Qian B, Li D. Global, regional, and national burden of acute myeloid leukemia, 1990–2021: a systematic analysis for the global burden of disease study 2021. Biomark Res. 2024;12(1):101. Doi: http://doi.org/10.1186/s40364-024-00649-y.
  6. Maktoof SA, Al-Ammar NS, Al-Kashwan TAJ, Jumaa AK. A comprehensive study of incidence and clinical manifestations among Iraqi patients with newly diagnosed AML in 2022. The Medical Journal of Basrah University. 2024;42(1):76–82. Doi: https://doi.org/10.33762/mjbu.2024.147583.1202.
  7. Vakiti A, Reynolds SB, Mewawalla P. Acute myeloid leukemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507875/.
  8. Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol. 2009;37(6):649-58. Doi: http://doi.org/10.1016/j.exphem.2009.04.002.
  9. Hernández Borrero LJ, El-Deiry WS. Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188556. Doi: https://doi.org/10.1016/j.bbcan.2021.188556.
  10. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1): a001008. Doi: https://doi.org/10.1101/cshperspect.a001008.
  11. Liu J, Zhang C, Wang J, et al., The regulation of ferroptosis by tumor suppressor p53 and its pathway. Int J Mol Sci. 2020;21(21):8387. https://doi.org/ 10.3390/ijms21218387.
  12. Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015 Feb 26;518(7540):552-555. Doi: http://doi.org/10.1038/nature13968.
  13. Latif AL, Newcombe A, Li S, Gilroy K, Robertson NA, Lei X, et al. BRD4-mediated repression of p53 is a target for combination therapy in AML. Nat Commun. 2021;12(1):241. Doi: https://doi.org/10.1038/s41467-020-20378-8.
  14. Kim A, Nemeth E. New insights into iron regulation and erythropoiesis. Curr Opin Hematol. 2015;22(3):199-205. Doi: https://doi.org/10.1097/MOH.0000000000000132.
  15. Puig S, Ramos-Alonso L, Romero AM, Martínez-Pastor MT. The elemental role of iron in DNA synthesis and repair. Metallomics. 2017;9(11):1483–500. Doi: https://doi.org/10.1039/c7mt00116a.
  16. Shen J, Sheng X, Chang Z, Wu Q, Wang S, Xuan Z, et al. Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function. Cell Rep. 2014;7(1):180–93. Doi: http://doi.org/10.1016/j.celrep.2014.02.042
  17. Liang SX, Richardson DR. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis. 2003;24(10):1601–14. Doi: https://doi.org/10.1093/carcin/bgg116.
  18. Lewis JE, Pozdnyakova O. Digital assessment of peripheral blood and bone marrow aspirate smears. Int J Lab Hematol. 2023;45 Suppl 2:50-58. doi: https://doi.org/10.1111/ijlh.14082.
  19. Abramowitz J, Neuman T, Perlman R, Ben-Yehuda D. Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal acute myeloid leukemia and acute promyelocytic leukemia. BMC Med Genomics. 2017;10:18. Doi: https://doi.org/10.1186/s12920-017-0249-2.
  20. Alaa G, Hamzah IH, Matti BF. Hematological Biomarkers in Acute Myeloid Leukemia: A Comparative Study of New and Relapsed Iraqi Cases. Al-Kufa University Journal for Biology. 2025;17(3):1–7. Doi: https://doi.org/10.36320/ajb/v17.i3.19474.
  21. Narayanan D, Weinberg OK. How I investigate acute myeloid leukemia. Int J Lab Hematol. 2020;42(1):3–15. https://doi.org/10.1111/ijlh.13135.
  22. Jebur LA, Al-Rubaie HA. Assessment of Serum P53 Protein Level in Adult Patients with Acute Myeloid Leukemia in Correlation with Response to Treatment. J Fac Med Baghdad. 2024;66(3):363–7. Doi: https://doi.org/10.32007/jfacmedbaghdad.6632345.
  23. Georgantzinos E, Karantanos T. Molecular and Clinical Insights into TP53-Mutated MDS and AML. Int J Mol Sci. 2025 Nov 7;26(22):10818. Doi: https://doi.org/10.3390/ijms262210818.
  24. Rajagopalan A, Feng Y, Gayatri MB, et al. A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice. J Clin Invest. 2023;134(1):e173116. Doi: https://doi.org/10.1172/JCI173116.
  25. Prokocimer M, Molchadsky A, Rotter V. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. Blood. 2017;130(6):699–712. Doi: https://doi.org/10.1182/blood-2017-02-763086.
  26. George B, Kantarjian H, Baran N, Krocker JD, Rios A. TP53 in acute myeloid leukemia: molecular aspects and patterns of mutation. Int J Mol Sci. 2021;22(19):10782. Doi: https://doi.org/10.3390/ijms221910782.
  27. Post SM, Kornblau SM, Quintás-Cardama A. p53 pathway dysfunction in AML: beyond TP53 mutations. Oncotarget. 2017;8(67):112052–8. Doi: https://doi.org/10.18632/oncotarget.22713.
  28. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022;140(12):1345–77. Doi: https://doi.org/10.1182/blood.2022016867.
  29. Abdel-Aziz MM. Clinical significance of serum p53 and epidermal growth factor receptor in patients with acute leukemia. Asian Pac J Cancer Prev. 2013;14(7):4295-9. Doi: https://doi.org/10.7314/apjcp.2013.14.7.4295.
  30. Pourebrahim R, Montoya RH, Akiyama H, Ostermann L, Khazaei S, Muftuoglu M, et al. Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult mice. Cell Rep Med. 2024;5(6):101579. Doi: https://doi.org/10.1016/j.xcrm.2024.101558.
  31. Hafner A, Bulyk ML, Jambhekar A, Lahav G. The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol. 2019;20(4):199–210. Doi: https://doi.org/10.1038/s41580-019-0110-x.
  32. Stengel A, Meggendorfer M, Walter W, Baer C, Nadarajah N, Hutter S, et al. Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS. Blood Adv. 2023 Sep 26;7(18):5540-5548. Doi: https://doi.org/10.1182/bloodadvances.2023010312.
  33. Weber S, Parmon A, Kurrle N, Schnütgen F, Serve H. The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia. Front Immunol. 2021;19;11:627662. Doi: https://doi.org/10.3389/fimmu.2020.627662.
  34. Lopes M, Duarte TL, Teles MJ, Mosteo L, Chacim S, Aguiar E, et al. Loss of erythroblasts in acute myeloid leukemia causes iron redistribution with clinical implications. Blood Adv. 2021 Aug 24;5(16):3102-3112. Doi: https://doi.org/10.1182/bloodadvances.2021004373.
  35. Wang F, Lv H, Zhao B, Zhou L, Wang S, Luo J, et al. Iron and leukemia: new insights for future treatments. J Exp Clin Cancer Res. 2019;13;38(1):406. Doi: https://doi.org/10.1186/s13046-019-1397-3.
  36. Pourcelot E, El Samra G, Mossuz P, Moulis JM. Molecular Insight into Iron Homeostasis of Acute Myeloid Leukemia Blasts. Int J Mol Sci. 2023 Sep 19;24(18):14307. Doi: https://doi.org/10.3390/ijms241814307.
  37. Nemeth E, Ganz T. Hepcidin and iron in health and disease. Annu Rev Med. 2023;74:261–277. doi: https://doi.org/10.1146/annurev-med-043021-032816.
  38. Laubach K, Zhang J, Chen X. The p53 Family: A Role in Lipid and Iron Metabolism. Front Cell Dev Biol. 2021;29;9:715974. Doi: https://doi.org/10.3389/fcell.2021.715974.
  39. Chomczyk M, Gazzola L, Dash S, Firmanty P, George BS, Mohanty V, et al. Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment. Front Pharmacol. 2024;5(15):1409210. Doi: https://doi.org/10.3389/fphar.2024.1409210.
  40. Shireen I, Komal S, Ansari AM, Meraj L. Frequency of complete remission after standard 3+7 induction therapy in patients with acute myeloid leukemia. Pak J Med Sci. 2022;38(5):1325–9. Doi: https://doi.org/10.12669/pjms.38.5.5249.
  41. Mrózek K, Kohlschmidt J, Blachly JS, Nicolet D, Carroll AJ, Archer KJ, et al. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 2023 Apr;37(4):788-798. Doi: http://doi.org/10.1038/s41375-023-01846-8.
  42. Hussein GA, Jawad AM. Impact of aberrant antigens expression on remission rate after first induction course of chemotherapy in de novo adult acute myeloid leukemia. Iraqi Journal of Hematology 2021;10(2):118-122. Doi: https://doi.org/10.4103/ijh.ijh_17_21.
  43. Mirzayans R, Andrais B, Kumar P, Murray D. Significance of wild-type p53 signaling in suppressing apoptosis in response to chemical genotoxic agents: impact on chemotherapy outcome. Int J Mol Sci. 2017;18(5):928. Doi: https://doi.org/10.3390/ijms18050928.
  44. Zawacka JE. p53 biology and reactivation for improved therapy in MDS and AML. Biomark Res. 2024;12(1):34. Doi: https://doi.org/10.1186/s40364-024-00579-9.
  45. Zhang C, Liu J, Xu D, Zhang T, Hu W, Feng Z. Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol. 2020;12(9):674-687. Doi: https://doi.org/10.1093/jmcb/mjaa040.
  46. Hall C, Muller PAJ. The Diverse Functions of Mutant 53, Its Family Members and Isoforms in Cancer. Int J Mol Sci. 2019;20(24):6188. Doi: https://doi.org/10.3390/ijms20246188.
  47. Georgantzinos E, Karantanos T. Molecular and Clinical Insights into TP53-Mutated MDS and AML. International Journal of Molecular Sciences. 2025; 26(22):10818. Doi: https://doi.org/10.3390/ijms262210818.
  48. Wang F, Lv H, Zhao B, Zhou L, Wang S, Luo J, et al. Iron and leukemia: new insights for future treatments. J Exp Clin Cancer Res. 2019 Sep 13;38(1):406. Doi: https://doi.org/10.1186/s13046-019-1397-3.
  49. La QD, Faltas M, Zavareh A, Gul Z, Uzzi U, Kahlam JS, et al. Iron Overload, Clonal Hematopoiesis, and Cancer Risk in Aging and Transfusion-Dependent Populations: A Literature Review. Cureus. 2025;17(6):e85936. Doi: https://doi.org/10.7759/cureus.85936.
  50. Cordani M, Butera G, Pacchiana R, Masetto F, Mullappilly N, Riganti C, et al. Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells. Biomolecules. 2020;10(3):361. Doi: https://doi.org/10.3390/biom10030361.
  51. Jia Y, Li L, Li Y, Zhu X, Xu B, Li Q, Zhang H. Iron overload mediates cytarabine resistance in AML by inhibiting the TP53 signaling pathway: Iron overload mediates cytarabine resistance. Acta Biochimica et Biophysica Sinica. 2025 Feb 28;57(4):646.Doi: https://doi.org/10.3390/biom10030361.
  52. Zhang J, Xu Z, Yu L, Chen M, Li K. Assessment of the potential diagnostic value of serum p53 antibody for cancer: a meta-analysis. PLoS One. 2014;9(6):e99255. Doi: https://doi.org/10.1371/journal.pone.0099255.
  53. Tashakori M, Kadia T, Loghavi S, Daver N, Kanagal-Shamanna R, Pierce S, et al. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022;140(1):58-72. Doi: https://doi.org/10.1182/blood.2021013983.
  54. Daver NG, Maiti A, Kadia TM, Vyas P, Majeti R, Wei AH, et al. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discov. 2022;12(11):2516-2529. Doi: https://doi.org/10.1158/2159-8290.CD-22-0332.
  55. Calabrese C, Panuzzo C, Stanga S, Andreani G, Ravera S, Maglione A, et al. Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells. Int J Mol Sci. 2020;21(20):7674. Doi: https://doi.org/10.3390/ijms21207674.

Authors

Duaa Saad Al-Kawaz

Department of Pathology, College of Medicine, University of Mosul, Mosul, Iraq

ORCID
Dr. Sadeel Osama Al-Shabkhoon

Teaching Medical Research Hospital, Nineveh Health Directorate, Mosul, Iraq

Identifiers

DOI: 10.33899/acmm.v48.i1.60326

Download this PDF file
PDF

Statistics

How to Cite

1.
Evaluation of P53 Level and It’s Relation to Iron Status in Acute Myeloid Leukemia. Ann. coll. Med. Mosul [Internet]. 2026 Jun. 30 [cited 2026 Jul. 18];48(1):78-89. Available from: https://mmed.uomosul.edu.iq/index.php/mmed/article/view/60326

How to Cite

1.
Evaluation of P53 Level and It’s Relation to Iron Status in Acute Myeloid Leukemia. Ann. coll. Med. Mosul [Internet]. 2026 Jun. 30 [cited 2026 Jul. 18];48(1):78-89. Available from: https://mmed.uomosul.edu.iq/index.php/mmed/article/view/60326